What's the difference between Ozempic and Wegovy?

Do Ozempic and Wegovy actually contain the same thing?

Yes, both products contain semaglutide, a GLP-1 receptor agonist that slows gastric emptying, reduces appetite signalling and influences blood-sugar regulation. The mechanism is identical. Where they diverge is in their licensed dose, their approved indication and the regulatory pathway Novo Nordisk used to bring each to market.

Ozempic is approved by the MHRA for type 2 diabetes management. Its weekly doses top out at 2 mg. Wegovy, by contrast, was developed and licensed specifically for weight management: its maintenance dose is 2.4 mg weekly (with a new 7.2 mg option now also approved for adults with obesity (see below), and its clinical trial programme) the STEP studies, was designed entirely around weight outcomes. The STEP 1 trial, published in the New England Journal of Medicine, reported an average weight reduction of around 15% over 68 weeks at the 2.4 mg dose.

A common misconception is that Ozempic and Wegovy are interchangeable for weight loss, and that Ozempic is simply the cheaper version you can ask for instead. That is not how UK prescribing works. A prescriber cannot lawfully issue Ozempic for weight loss off-label when Wegovy exists as the licensed alternative; and Ozempic has historically faced supply pressures partly because of exactly this kind of off-label demand. If you want to understand whether there is any practical difference between Ozempic and Wegovy beyond the licence, that question is explored in more detail separately. The NHS medicines page for semaglutide is clear on the distinction between the two brands.

Does the different licence change who can be prescribed each one?

Substantially, yes. Ozempic is prescribed to adults with type 2 diabetes, usually alongside other diabetes medicines or lifestyle measures. Weight loss may occur as a secondary effect, but that is not the treatment's purpose under its UK authorisation.

Wegovy's licence covers adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, raised cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. NICE has recommended Wegovy (TA875) for use within specialist weight management services, with specific criteria around BMI and comorbidities and a maximum treatment duration of two years in that NHS pathway.

Private prescribing through a registered pharmacy follows the licensed indication rather than NICE's NHS commissioning thresholds, which means the route to treatment can be faster, but eligibility still depends on a clinical assessment. If you are curious about side-by-side eligibility criteria across semaglutide products, the Wegovy vs Ozempic eligibility breakdown covers this in more depth.

Rybelsus, the oral form of semaglutide, is also worth mentioning briefly here: it carries a diabetes licence at doses of 3 mg, 7 mg and 14 mg, entirely separate from Wegovy tablets, which are the weight-loss oral semaglutide product approved in June 2026 at a different dosing schedule.

How do their side-effect and safety profiles compare?

Because the molecule is the same, the side-effect profile overlaps heavily. Gastrointestinal effects (nausea, looser stools, constipation, indigestion, occasional vomiting) are the most commonly reported with both, and tend to be most noticeable when starting or increasing a dose, generally settling as the body adjusts.

The MHRA issued a Drug Safety Update in January 2026 reinforcing that acute pancreatitis, while infrequent, is a known risk with GLP-1 receptor agonists: severe stomach pain, particularly pain that spreads to the back and does not ease, warrants urgent medical attention. This applies to both Ozempic and Wegovy given the shared mechanism. Patients can report any suspected side effects directly through the MHRA's Yellow Card scheme.

The higher maintenance doses used in Wegovy's weight-management programme (2.4 mg, and now 7.2 mg for some patients) mean the GI burden during titration can be a little more pronounced than at the lower doses used in Ozempic's diabetes regimens, something prescribers factor in when reviewing suitability. Women using oral contraceptives should discuss contraception choices with their prescriber before starting semaglutide, as advice varies depending on the clinical picture.

Which semaglutide product can a UK pharmacy legitimately prescribe for weight loss?

Only Wegovy. Ozempic is not dispensed by nume for weight management because it is not licensed for that purpose in the UK. For a thorough look at what the differences between Ozempic and Wegovy actually are, including how their dosing schedules and clinical programmes diverge, that is covered in full separately. This page is educational, if you arrived here hoping to access Ozempic as a weight-loss treatment, the honest answer is that Wegovy is the right product, and Mounjaro (tirzepatide) is the other UK-licensed option worth comparing.

Mounjaro works on two gut-hormone pathways rather than one, and the SURMOUNT-5 head-to-head trial showed it produced greater average weight loss than semaglutide 2.4 mg over 72 weeks. You can read a fuller look at how these two treatments sit alongside each other on the Mounjaro versus Wegovy comparison page.

At nume, a GPhC-registered Independent Prescriber reviews your consultation the same day, a named clinician, not a decision algorithm. Once approved, treatment is dispatched by 12 pm for free next-working-day DPD delivery in plain packaging. If you want to understand whether Wegovy could be the right clinical fit for you, the place to start is a free consultation.

Which of these (or whether tirzepatide is a better fit) is a clinical decision our prescribers make with you, based on your full health picture. If you are still weighing up the two semaglutide brands, the page covering the difference between Wegovy and Ozempic goes into further detail on how they compare in practice. You can explore both licensed options on the treatment page, or read about how to access Wegovy through a regulated UK pharmacy if you want to understand that process first. Our clinical team is available to answer questions before you commit to anything.